The development of combination treatments is widely viewed by both industry and academia to be the critical path to unlocking the full promise of cancer immunotherapies. Despite this widespread consensus, the complexity of developing combination cancer immunotherapies presents several challenges.
With so many treatments targeting different immune pathways and mechanisms, how do you select which ones to bring together? How do you minimize the risks to companies and patients when testing two or more experimental agents in combination? And what tools need to be incorporated into clinical trial designs to enable combination immunotherapies to be tested more rapidly, cost-effectively, and in a way that provides sufficient data to assess clinical benefit and inform future development decisions?
The 2013 Scientific Colloquium of the CRI Cancer Immunotherapy Consortium, Entering the Era of Combination Therapies: Practical Implementation, will bring together leaders from the regulatory, scientific, and business communities to present new methodological tools, leading-edge scientific data from ongoing combination studies, and innovative models of academic-industry collaboration that are helping to overcome these and other challenges to optimizing combination cancer therapies for the benefit of patients.
Special thanks to our meeting sponsors: